COMPANY

TesoRx

HQ: Menlo Park, CA source · tesorx.com ↗

Keywords: drug delivery Hypogonadism Male Hypogonadism Gonadal Disorders Endocrine System Diseases Testosterone Deficiency TSX-002 TSX-011

Location: Menlo Park, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Nov 6, 2017 Trial start 1: A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males source ↗
2014-09 Trial start Phase 2: Oral Testosterone for the Treatment of Hypogonadism in Males source ↗
2012-10 Trial start Phase 2: Oral Testosterone for the Treatment of Hypogonadism source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03335254	A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males	1	Terminated	Nov 6, 2017	May 3, 2018 (actual)
NCT02222558	Oral Testosterone for the Treatment of Hypogonadism in Males	Phase 2	Completed	2014-09	2015-04 (actual)
NCT01717768	Oral Testosterone for the Treatment of Hypogonadism	Phase 2	Completed	2012-10	2014-08 (actual)